BioSpace News Archive

Revolo Biotherapeutics (“Revolo Bio” or the “Company”) today announced that the last patient has completed the twelve-week Phase 2a clinical trial evaluating the safety and efficacy of the company’s immune-resetting drug, ‘1104, in allergic disease.

Vaxxinity, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) today announced positive safety data from the first cohort of the CHASE (Corneal Healing After SEcretome therapy) Phase 2b clinical trial evaluating KPI-012, a human mesenchymal stem cell secretome (MCS-S), for the treatment of persistent corneal epithelial defect (PCED).

Pliant Therapeutics, Inc. today announced that the Company will present three scientific posters at the upcoming 2023 American Thoracic Society (ATS) International Conference, taking place May 19-24, 2023, in Washington, DC.

LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the maytansinoid-based drug delivery systems.